Summary
873.31
27.12
(3.20%)
07/21/2026
argenx SE (ARGX)Key Facts
Performance
Historical returns1D
3.20%
1W
-1.54%
1M
n/a
3M
1.41%
6M
4.51%
1Y
49.47%
5Y
172.64%
Snapshot
Key statisticsClose
873.31
Change
27.12
Change %
3.20%
Open
862.38
Day Range
859.42 – 877.58
Volume
213,214
Avg Vol (20d)
356,586
Rel Vol
0.60x
52W Range
560.91 - 953.58
vs 52W High
-8.42%
vs 52W Low
55.69%
Gap
0.80
Market Cap
USD 52.80B
Beta
-0.11
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 1× | 0.00% |
| 1-Month | 3× | -7.06% |
| 3-Month | 11× | -7.06% |
| 6-Month | 10× | -7.06% |
| YTD | 7× | -7.06% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 33× | -7.06% |
| 2-Year | 59× | -7.06% |
| 3-Year | 51× | -7.06% |
| 5-Year | 84× | -7.06% |
| 10-Year | 165× | -7.06% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 4.32B
+98.7% YoY
Net Income
USD 1.34B
-6,310.0% YoY
EPS
21.94
+57.6% YoY
Gross Margin
89.1%
Operating Margin
23.4%
Net Margin
31.1%
EBITDA
USD 1.01B
Free Cash Flow
USD 876.01M
20.3% margin
ROE
18.4%
ROA
15.5%
Debt / Equity
0.01x
net debt -USD 3.41B
Cash & Equiv.
USD 3.49B
Fundamental Ratings
MainA-
RecommendedBuy
DCFNeutral
ROEStrong Buy
ROAStrong Buy
Debt/EquityBuy
P/ESell
P/BStrong Sell
Latest Earnings
- ARGX reported last earnings on 2026-05-07.
- EPS of $5.9 vs $6.27 estimated — surprise $-0.37.
- Revenue of $2,406M vs $1,449M estimated — surprise $957M.
News
All newsBoston Common Asset Management LLC Takes Position in argenex SE $ARGX
Boston Common Asset Management LLC bought a new position in argenex SE (NASDAQ: ARGX) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,753 shares of the company's stock, valued at approximately $2,741,000. Other large investors have also...
Artisan Mid Cap Fund Q2 2026 Performance Review
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in...
Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company. The collaboration will see argenx get access to Chai's AI platform and apply de novo...
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.
Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a strong summer for stocks, telling clients the Q3 sets up nicely for a rally before midterm...
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the...
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following switch to biweekly dosing Cross-indication analysis of efgartigimod data across rheumatology studies...
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune...
argenx to Present at Upcoming Investor Conferences
May 27, 2026Amsterdam, the Netherlands - argenx (Euronext and Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences...